Is EVMN or DYN more profitable?

Evommune's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Dyne Therapeutics N/A -58.28% -46.77%

Does the media refer more to EVMN or DYN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Evommune. MarketBeat recorded 15 mentions for Dyne Therapeutics and 11 mentions for Evommune. Dyne Therapeutics' average media sentiment score of 0.09 beat Evommune's score of -0.15 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EVMN or IDYA more profitable?

Evommune's return on equity of 0.00% beat IDEAYA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A IDEAYA Biosciences N/A -14.24% -13.09%

Does the media favor EVMN or IDYA?

In the previous week, Evommune had 9 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 11 mentions for Evommune and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, EVMN or ALMS?

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 35.72 -$68.87M -$9.50 N/A Alumis $24.05M 140.48 -$243.32M -$1.98 N/A

Is EVMN or ALMS more profitable?

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Alumis -2,825.70% -88.79% -70.72%

Does the media favor EVMN or ALMS?

In the previous week, Evommune had 8 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Evommune and 3 mentions for Alumis. Alumis' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EVMN or ADPT?

In the previous week, Evommune had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Evommune and 8 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.60 beat Evommune's score of -0.15 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, EVMN or QURE?

Evommune has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 35.72 -$68.87M -$9.50 N/A uniQure $16.10M 163.79 -$198.97M -$3.48 N/A

Is EVMN or QURE more profitable?

Evommune has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Evommune's return on equity of 0.00% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A uniQure -1,154.42% -145.81% -27.15%

Does the media prefer EVMN or QURE?

In the previous week, uniQure had 16 more articles in the media than Evommune. MarketBeat recorded 27 mentions for uniQure and 11 mentions for Evommune. uniQure's average media sentiment score of 0.73 beat Evommune's score of -0.15 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evommune (EVMN) Competitors

$12.89 +0.07 (+0.56%)

Closing price 03:59 PM Eastern

Extended Trading

$12.75 -0.14 (-1.09%)

As of 07:56 PM Eastern

Compare

EVMN vs. DYN, IDYA, ALMS, ADPT, and QURE

Should you buy Evommune stock or one of its competitors? MarketBeat compares Evommune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evommune include Dyne Therapeutics (DYN), IDEAYA Biosciences (IDYA), Alumis (ALMS), Adaptive Biotechnologies (ADPT), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Evommune compare to Dyne Therapeutics?

Evommune (NYSE:EVMN) and Dyne Therapeutics (NASDAQ:DYN) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Dyne Therapeutics had 4 more articles in the media than Evommune. MarketBeat recorded 15 mentions for Dyne Therapeutics and 11 mentions for Evommune. Dyne Therapeutics' average media sentiment score of 0.09 beat Evommune's score of -0.15 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evommune's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Dyne Therapeutics	N/A	-58.28%	-46.77%

Evommune currently has a consensus price target of $45.63, indicating a potential upside of 253.90%. Dyne Therapeutics has a consensus price target of $34.17, indicating a potential upside of 48.10%. Given Evommune's higher possible upside, analysts plainly believe Evommune is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

96.7% of Dyne Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evommune has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Summary

Evommune beats Dyne Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Evommune compare to IDEAYA Biosciences?

Evommune (NYSE:EVMN) and IDEAYA Biosciences (NASDAQ:IDYA) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Evommune has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
IDEAYA Biosciences	$218.71M	15.12	-$113.70M	-$1.60	N/A

Evommune's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
IDEAYA Biosciences	N/A	-14.24%	-13.09%

98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Evommune presently has a consensus price target of $45.63, indicating a potential upside of 253.90%. IDEAYA Biosciences has a consensus price target of $50.69, indicating a potential upside of 34.63%. Given Evommune's stronger consensus rating and higher probable upside, equities analysts clearly believe Evommune is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Evommune had 9 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 11 mentions for Evommune and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evommune beats IDEAYA Biosciences on 9 of the 15 factors compared between the two stocks.

How does Evommune compare to Alumis?

Evommune (NYSE:EVMN) and Alumis (NASDAQ:ALMS) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
Alumis	$24.05M	140.48	-$243.32M	-$1.98	N/A

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

Evommune presently has a consensus price target of $45.63, indicating a potential upside of 253.90%. Alumis has a consensus price target of $40.30, indicating a potential upside of 52.08%. Given Evommune's stronger consensus rating and higher possible upside, equities analysts plainly believe Evommune is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Evommune had 8 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Evommune and 3 mentions for Alumis. Alumis' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evommune beats Alumis on 9 of the 14 factors compared between the two stocks.

How does Evommune compare to Adaptive Biotechnologies?

Evommune (NYSE:EVMN) and Adaptive Biotechnologies (NASDAQ:ADPT) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Adaptive Biotechnologies has higher revenue and earnings than Evommune. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
Adaptive Biotechnologies	$276.98M	12.24	-$59.50M	-$0.33	N/A

In the previous week, Evommune had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Evommune and 8 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.60 beat Evommune's score of -0.15 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune currently has a consensus target price of $45.63, suggesting a potential upside of 253.90%. Adaptive Biotechnologies has a consensus target price of $20.50, suggesting a potential downside of 3.26%. Given Evommune's stronger consensus rating and higher probable upside, equities analysts plainly believe Evommune is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Evommune has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Evommune's return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Summary

Evommune beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks.

How does Evommune compare to uniQure?

Evommune (NYSE:EVMN) and uniQure (NASDAQ:QURE) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, uniQure had 16 more articles in the media than Evommune. MarketBeat recorded 27 mentions for uniQure and 11 mentions for Evommune. uniQure's average media sentiment score of 0.73 beat Evommune's score of -0.15 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
uniQure	$16.10M	163.79	-$198.97M	-$3.48	N/A

Evommune has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Evommune's return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
uniQure	-1,154.42%	-145.81%	-27.15%

Evommune presently has a consensus price target of $45.63, indicating a potential upside of 253.90%. uniQure has a consensus price target of $64.17, indicating a potential upside of 53.47%. Given Evommune's stronger consensus rating and higher probable upside, equities research analysts clearly believe Evommune is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Evommune and uniQure tied by winning 8 of the 16 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$461.76M	$3.11B	$4.45B	$23.33B
Dividend Yield	N/A	15.23%	17.12%	4.00%
P/E Ratio	-1.36	13.32	19.06	28.65
Price / Sales	35.72	2,864.06	167.68	21.94
Price / Cash	N/A	26.14	35.72	25.23
Price / Book	1.98	5.15	13.25	4.81
Net Income	-$68.87M	-$34.63M	$113.80M	$1.07B
7 Day Performance	-46.28%	1.07%	1.45%	1.74%
1 Month Performance	-34.96%	-1.24%	-2.29%	2.76%
1 Year Performance	N/A	12.63%	11.24%	19.96%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.2942 of 5 stars	$12.89 +0.6%	$45.63 +253.9%	N/A	$461.76M	$13M	N/A	45	News Coverage Analyst Downgrade
DYN Dyne Therapeutics	2.6085 of 5 stars	$20.61 +1.4%	$33.85 +64.2%	+151.0%	$3.36B	N/A	N/A	100	Insider Trade
IDYA IDEAYA Biosciences	3.5558 of 5 stars	$36.29 +0.0%	$50.69 +39.7%	+71.3%	$3.19B	$218.71M	N/A	80
ALMS Alumis	2.8679 of 5 stars	$25.03 +0.7%	$40.30 +61.0%	+782.1%	$3.17B	$24.05M	N/A	N/A	News Coverage
ADPT Adaptive Biotechnologies	2.4503 of 5 stars	$20.25 +4.7%	$20.33 +0.4%	+99.9%	$3.10B	$276.98M	N/A	790	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. DYN, IDYA, ALMS, ADPT, and QURE

How does Evommune compare to Dyne Therapeutics?

Summary

How does Evommune compare to IDEAYA Biosciences?

Summary

How does Evommune compare to Alumis?

Summary

How does Evommune compare to Adaptive Biotechnologies?

Summary

How does Evommune compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. DYN, IDYA, ALMS, ADPT, and QURE

How does Evommune compare to Dyne Therapeutics?

Does the media refer more to EVMN or DYN?

Is EVMN or DYN more profitable?

Do analysts prefer EVMN or DYN?

Do insiders and institutionals believe in EVMN or DYN?

Which has higher valuation & earnings, EVMN or DYN?

Summary

How does Evommune compare to IDEAYA Biosciences?

Which has preferable valuation & earnings, EVMN or IDYA?

Is EVMN or IDYA more profitable?

Do institutionals and insiders believe in EVMN or IDYA?

Do analysts recommend EVMN or IDYA?

Does the media favor EVMN or IDYA?

Summary

How does Evommune compare to Alumis?

Which has better valuation and earnings, EVMN or ALMS?

Is EVMN or ALMS more profitable?

Do analysts recommend EVMN or ALMS?

Does the media favor EVMN or ALMS?

Summary

How does Evommune compare to Adaptive Biotechnologies?

Which has better earnings and valuation, EVMN or ADPT?

Does the media favor EVMN or ADPT?

Do analysts rate EVMN or ADPT?

Do insiders & institutionals hold more shares of EVMN or ADPT?

Is EVMN or ADPT more profitable?

Summary

How does Evommune compare to uniQure?

Does the media prefer EVMN or QURE?

Which has higher valuation and earnings, EVMN or QURE?

Is EVMN or QURE more profitable?

Do analysts rate EVMN or QURE?

Do insiders and institutionals hold more shares of EVMN or QURE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools